p27: a barometer of signaling deregulation and potential predictor of response to targeted therapies

Clin Cancer Res. 2011 Jan 1;17(1):12-8. doi: 10.1158/1078-0432.CCR-10-0752. Epub 2010 Oct 21.

Abstract

Phosphorylation of the cyclin-dependent kinase inhibitor p27 by upstream mitogenic signaling pathways regulates its stability, localization, and biological function. In human cancers, loss of the antiproliferative action of p27 can arise through reduced protein levels and/or cytoplasmic mislocalization, leading to increased cell proliferation and/or cell migration, respectively. Reduced p27 expression levels and p27 mislocalization have potential prognostic and therapeutic implications in various types of human cancers. This review highlights mechanisms of functional deregulation of p27 by oncogenic signaling that provide an important molecular rationale for pathway targeting in cancer treatment.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Cell Movement
  • Cell Proliferation
  • Cyclin-Dependent Kinase Inhibitor p27 / metabolism*
  • Humans
  • Molecular Targeted Therapy*
  • Neoplasms / diagnosis
  • Neoplasms / metabolism*
  • Neoplasms / pathology
  • Neoplasms / therapy*
  • Phosphorylation
  • Prognosis
  • Signal Transduction* / drug effects

Substances

  • Cyclin-Dependent Kinase Inhibitor p27